Abstract
Background The left ventricular outflow tract (LVOT) and ascending aorta are spatially complex, with distinct pathologies and embryologic origins. Prior work examined genetics of thoracic aortic diameter in a single plane. We sought to elucidate the genetic basis for the diameter of the LVOT, the aortic root, and the ascending aorta.
Methods We used deep learning to analyze 2.3 million cardiac magnetic resonance images from 43,317 UK Biobank participants. We computed the diameters of the LVOT, the aortic root, and at six locations in the ascending aorta. For each diameter, we conducted a genome-wide association study and generated a polygenic score. Finally, we investigated associations between these polygenic scores and disease incidence.
Results 79 loci were significantly associated with at least one diameter. Of these, 35 were novel, and a majority were associated with one or two diameters. A polygenic score of aortic diameter approximately 13mm from the sinotubular junction most strongly predicted thoracic aortic aneurysm in UK Biobank participants (n=427,016; HR=1.42 per standard deviation; CI=1.34-1.50, P=6.67×10−21). A polygenic score predicting a smaller aortic root was predictive of aortic stenosis (n=426,502; HR=1.08 per standard deviation; CI=1.03-1.12, P=5×10−6).
Conclusions We detected distinct common genetic loci underpinning the diameters of the LVOT, the aortic root, and at several segments in the ascending aorta. We spatially defined a region of aorta whose genetics may be most relevant to predicting thoracic aortic aneurysm. We further described a genetic signature that may predispose to aortic stenosis. Understanding the genetic contributions to the diameter of the proximal aorta may enable identification of individuals at risk for life-threatening aortic disease and facilitate prioritization of therapeutic targets.
Competing Interest Statement
Dr. Pirruccello has served as a consultant for Maze Therapeutics. Dr. Lubitz receives sponsored research support from Bristol Myers Squibb / Pfizer, Bayer AG, Boehringer Ingelheim, and Fitbit, and has consulted for Bristol Myers Squibb / Pfizer and Bayer AG, and participates in a research collaboration with IBM. Dr. Ng is employed by IBM Research. Dr. Batra receives sponsored research support from Bayer AG and IBM, and has consulted for Novartis and Prometheus Biosciences. Dr. Ho has received research grant support from Bayer AG focused on machine-learning and cardiovascular disease, and research supplies from EcoNugenics. Dr. Philippakis is supported by a grant from Bayer AG to the Broad Institute focused on machine learning for clinical trial design. Dr. Ellinor is supported by a grant from Bayer AG to the Broad Institute focused on the genetics and therapeutics of cardiovascular diseases. Dr. Ellinor has also served on advisory boards or consulted for Bayer AG, Quest Diagnostics, MyoKardia and Novartis. Remaining authors report no disclosures.
Funding Statement
This work was supported by the Fondation Leducq (14CVD01), and by grants from the National Institutes of Health to Dr. Pirruccello (K08HL159346), Dr. Ellinor (1RO1HL092577, K24HL105780) and Dr. Ho (R01HL134893, R01HL140224, K24HL153669). This work was also supported by a Sarnoff Cardiovascular Research Foundation Scholar Award to Dr. Pirruccello. Dr. Nauffal is supported by NIH grant 5T32HL007604-35. Dr. Lubitz is supported by NIH grant R01HL139731 and American Heart Association 18SFRN34250007. This work was supported by a grant from the American Heart Association Strategically Focused Research Networks to Dr. Ellinor. Dr. Lindsay is supported by the Fredman Fellowship for Aortic Disease and the Toomey Fund for Aortic Dissection Research. This work was funded by a collaboration between the Broad Institute and IBM Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study involves only openly available human data, which can be obtained from: the UK Biobank (https://www.ukbiobank.ac.uk)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† These authors jointly supervised this work.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
